Semaglutide 1.7mg Shows Strong Efficacy for Adolescent Obesity Treatment
Background
Adolescent obesity is a significant and growing public health challenge, often leading to serious comorbidities like type 2 diabetes and cardiovascular disease. While semaglutide, a GLP-1 receptor agonist (a medication that mimics a natural hormone to regulate appetite and blood sugar), has proven highly effective for obesity in adults, its specific efficacy, safety, and optimal dosing in the younger population remained largely unexplored. This study aimed to evaluate the effectiveness and safety of semaglutide 1.7 mg in adolescents with obesity.
Results
At the 68-week mark, adolescents treated with semaglutide 1.7 mg demonstrated a mean body weight reduction of 15.3% from baseline. This was significantly superior to the placebo group, which saw only a 2.4% reduction, resulting in an estimated treatment difference of -12.9 percentage points (95% CI: -14.5 to -11.3; p<0.001). A remarkable 82% of adolescents receiving semaglutide achieved ≥5% weight loss, a clinically meaningful threshold, compared to just 20% in the placebo group (OR 18.5; p<0.001). The pharmacokinetic profile confirmed exposure levels comparable to adults, and the safety profile was consistent with known adult data, primarily involving mild to moderate gastrointestinal adverse events such as nausea and vomiting.
Why It Matters
This study provides compelling evidence that semaglutide 1.7 mg is a highly effective and generally well-tolerated treatment option for adolescent obesity, a condition with limited pharmacological interventions. Given the significant health risks associated with adolescent obesity, these findings are particularly impactful for clinical practice. This research strongly supports the potential for semaglutide to become a crucial therapeutic tool in clinical practice for adolescents struggling with obesity. Future steps will likely involve long-term follow-up studies to assess sustained benefits and further real-world implementation to understand broader applicability across diverse adolescent populations.